Summary
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Alkermes NASDAQ: ALKS executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for a planned leadership transition.
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Farallon Capital Farallon Capital Management LLC | 20,800 | $686,816 | $934,336 | $247,520 | 36.04% |
 John H. Burbank III Passport Capital LLC | 10.01M | $270.05M | $449.75M | $179.7M | 66.55% |
 Bridgewater Associates LP Bridgewater Associates LP | 83,806 | $2.34M | $3.76M | $1.42M | 60.54% |
 Jeffrey Gundlach DoubleLine Capital LP | 100,000 | $2.16M | $4.49M | $2.33M | 107.96% |
| YA Yinka Akinsola Blue Trust Inc. | 255 | $7,323 | $11,454.6 | $4,131.6 | 56.42% |
Alkermes plc (ALKS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alkermes plc ever had a stock split?
Alkermes plc Profile
| Biotechnology Industry | Healthcare Sector | Richard F. Pops CEO | NASDAQ (NGS) Exchange | G01767105 CUSIP |
| US Country | 1,800 Employees | - Last Dividend | 15 May 2000 Last Split | 16 Jul 1991 IPO Date |
Overview
Alkermes plc stands out as a pivotal player in the biopharmaceutical sector, dedicated to discovering, developing, and commercializing innovative pharmaceutical solutions aimed at fulfilling the unmet medical necessities of patients. The company's operations span across the United States, Ireland, and other global territories, focusing on significant therapeutic areas. Founded in 1987, with its headquarters located in Dublin, Ireland, Alkermes plc has carved a niche for itself by concentrating on the treatment of alcohol and opioid dependencies, schizophrenia, and bipolar I disorder. Through its dynamic portfolio of proprietary commercial products and a robust pipeline of clinical and preclinical candidates, Alkermes plc endeavors to transform the therapeutic landscape of neurological disorders. Moreover, the company fosters strategic collaboration agreements with prestigious entities such as Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International, leveraging its proprietary technology platforms to assist third parties in developing, commercializing, and manufacturing their products.
Products and Services
- ARISTADA: An innovative intramuscular injectable suspension, ARISTADA is meticulously designed for the treatment of schizophrenia. It represents a cornerstone in Alkermes plc’s portfolio, offering sustained relief and management of symptoms associated with this complex mental health condition.
- ARISTADA INITIO: Tailored for adults diagnosed with schizophrenia, ARISTADA INITIO embodies an enhanced treatment solution to initiate and stabilize patients. This formulation underscores Alkermes plc's commitment to advancing psychiatric care and improving patient outcomes through targeted therapy.
- VIVITROL: Manifesting a pioneering approach to overcoming alcohol and opioid dependence, VIVITROL is an extended-release, injectable medication. Its mechanism of action provides a non-addictive treatment pathway, significantly contributing to the prevention of relapse in individuals striving for recovery.
- LYBALVI: Emerging as a groundbreaking oral atypical antipsychotic candidate, LYBALVI is intended for the treatment of adults suffering from schizophrenia and bipolar I disorder. This promising product candidate exemplifies Alkermes plc’s relentless drive towards introducing novel therapies that encapsulate both safety and efficacy.
